Cervical Cancer: Advanced Stage and Relapse Treatment – Standard and Experimental Therapy

  • Kimberly L. Levinson
  • Peter G. RoseEmail author


Cervical cancer is a common gynecologic cancer in women greater than age 65. The standard treatment for advanced disease in the general population is chemoradiation, and evidence suggests that elderly patients tolerate radiation therapy well. More prospective trials are needed in the elderly population to determine the superiority of chemoradiation over radiation alone or neoadjuvant chemotherapy followed by surgery. The standard treatment of metastatic or recurrent cervical cancer is chemotherapy. While studies suggest that age alone should not influence the use of chemotherapy in the elderly population, physiologic changes, medical comorbidities, and performance status of each individual must be considered. Dose reductions or altered regimens may therefore be appropriate. Several new therapeutic drugs and strategies are currently under investigation for advanced disease as well as metastatic and recurrent disease, and prospective evidence specific to this population will be needed to evaluate the efficacy of these strategies for elderly women with cervical cancer.


Cervical cancer Elderly Chemoradiation Chemotherapy 


  1. 1.
    Park JH, Kim YS, Ahn SD, Choi EK, Shin SS, Kim YT, Kim YM, Kim JH, Yi SY, Nam JH. Concurrent chemoradiotherapy or radiotherapy alone for locally advanced cervical cancer in elderly women. Tumori. 2010;96(6):959–65.PubMedGoogle Scholar
  2. 2.
    Nordin AJ, Chinn DJ, Moloney I, Naik R, de Barros Lopes A, Monaghan JM. Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol. 2001;81(3):447–55.PubMedCrossRefGoogle Scholar
  3. 3.
    McGonigle KF, Lagasse LD, Karlan BY. Ovarian, uterine, and cervical cancer in the elderly woman. Clin Geriatr Med. 1993;9(3):115–30.PubMedGoogle Scholar
  4. 4.
    Trimble EL, Harlan LC, Clegg LX. Untreated cervical cancer in the United States. Gynecol Oncol. 2005;96(2):271–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Tambaro R, Scambia G, Di Maio M, Pisano C, Barletta E, Iaffaioli VR, Pignata S. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit Rev Oncol Hematol. 2004;52:33–44.PubMedCrossRefGoogle Scholar
  6. 6.
    American Cancer Society Guidelines for the Early Detection of Cancer. American Cancer Society. Last Medical Review: 02/25/2010. Last Revised: 06/23/2011 ( Accessed 10/12/11.
  7. 7.
    ACOG Announces New Pap Smear and Cancer Screening Guidelines. American Congress of Obstetricians and Gynecologists. 2011. ( Accessed 10/12/11.
  8. 8.
    Geinitz H, Zimmermann FB, Molls M. Radiotherapy of the elderly patient. Radiotherapy tolerance and results in older patients. Strahlenther Onkol. 1999;175(3):119–27.PubMedCrossRefGoogle Scholar
  9. 9.
    Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev. 2005;31(5):380–402.PubMedCrossRefGoogle Scholar
  10. 10.
    Sakurai H, Mitsuhashi N, Takahashi M, Yamakawa M, Akimoto T, Hayakawa K, Niibe H. Radiation therapy for elderly patient with squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000;77(1):116–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Zachariah B, Balducci L. Radiation therapy of the older patient. Hematol Oncol Clin North Am. 2000;14(1):131–67.PubMedCrossRefGoogle Scholar
  12. 12.
    Ikushima H, Takegawa Y, Osaki K, Furutani S, Yamashita K, Kawanaka T, Kubo A, Kudoh T, Nishitani H. Radiation therapy for cervical cancer in the elderly. Gynecol Oncol. 2007;107:229–43.CrossRefGoogle Scholar
  13. 13.
    Lindegaard JC, Thranov IR, Engelholm SA. Radiotherapy in the management of cervical cancer in elderly patients. Radiother Oncol. 2000;56:9–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Pignon T, Horiot JC, Bolla M, Poppel H, Bartelink H, Roelofsen F, et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997;42:107–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Morris M, Eifel PH, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Eng J Med. 1999;340:1137–43.CrossRefGoogle Scholar
  16. 16.
    Peters III WA, Liu PY, Barrett RJ, et al. Cisplatin and 5-flourouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study. J Clin Oncol. 2000;18:1606–13.PubMedGoogle Scholar
  17. 17.
    Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, Clarke-Pearson DL, Liao SY. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–48.PubMedGoogle Scholar
  18. 18.
    Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Keys HM, Bundy BM, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Cheng M, Wu LY, Zhang WH, Huang MN, Zhang R. Clinical analysis of 215 elderly patients with cervical cancer. Zhonghua Zhong Liu Az Zhi. 2009;31(5):388–91.Google Scholar
  21. 21.
    Goodheart M, Jacobson G, Smith BJ, Zhou L. Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity. Int J Gynecol Cancer. 2008;18:95–103.PubMedCrossRefGoogle Scholar
  22. 22.
    Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cisplatin in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. Cancer. 1981;48:899–903.PubMedCrossRefGoogle Scholar
  23. 23.
    Cetina L, Garcia-Arias A, de Jesus Uribe M, Candelaria M, Rivera L, Onate-Ocana L, Coronel J, Duenas-Gonzalez A. Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. Eur J Gynecol Oncol. 2008;29(6): 608–12.Google Scholar
  24. 24.
    Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, Choi SC, Cho CK, Mam BH, Lee ED. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2012;82(4):1320.Google Scholar
  25. 25.
    Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-Analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomized trials. Eur J Cancer. 2003;39(17):2470–86.CrossRefGoogle Scholar
  26. 26.
    Manci N, Marchetti C, Di Tucci C, Giorgini M, Esposito F, Palaia I, Musella A, Perniola G, Carrone A, Benedetta-Panici P. A prospective phase II study of topotecan (Hycamtin) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2011;122:285–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Fox KV, Shah CA, Swisher EM, Garcia RL, Mandel LS, Gray HJ, Swensen RE, Goff BA. An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol. 2008;109:53–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control. 2007;14(1):32–43.PubMedGoogle Scholar
  29. 29.
    Moore KN, Frank SG, Alward EK, Landrum LM, Myers TK, Walker JL, Gold MA, McMeekin DS, Vesely SK, Mannel RS. Adjuvant chemotherapy for the “oldest old” ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009;115(7):1472–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Balducci L, Lyman GH, Ershler WB. Geriatric oncology. Philadelphia: JB Lippincott; 1992. p. 151–9.Google Scholar
  31. 31.
    Smorenburg CH, Ten Tije AJ, Verweij J, Bontenbal M, Mross K, Van Zomeren DM, Seeynaeve C, Sparreboom A. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer. 2003;39(2):196–202.PubMedCrossRefGoogle Scholar
  32. 32.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaqlia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol. 2009;71(3):233–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Uyar D, Frasure HE, Markman M, Von Gruenigen VE. Treatment patterns by decade of life in elderly women (> or  =  70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98(3):403–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Chen H, Cantor A, Meyer J, Beth-Corcoran M, Gerendys E, Cavanaugh D, Antonek S, Camarata A, Haley W, Balducci L, Extermann M. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 2003;15(97):1107–14.CrossRefGoogle Scholar
  35. 35.
    Fader AN, von Gruenigen V, Givvons H, Abushahin F, Starks D, Markman M, Belinson J, Rose P. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008;109:33–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Monk BJ, Wilmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol. 2010;116:181–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Monk BJ, Sill MW, McMeekin S, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB. Recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2009;27:4649–55.PubMedCrossRefGoogle Scholar
  38. 38.
    Moore DH, Tian C, Monk BJ, Long HJ, Omura G. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116(1):44–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Wildiers H. Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer. 2007;43:2235–41.PubMedCrossRefGoogle Scholar
  40. 40.
    Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol. 2009;36(2): 170–80.PubMedCrossRefGoogle Scholar
  41. 41.
    Moore KN, Herzog TJ, Lewin S, Guintoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105:299–303.PubMedCrossRefGoogle Scholar
  42. 42.
    Kitagawa R, Katsumata N, Shibata T, Nakanishi T, Nishimura S, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study JCOG0505). 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr 5006).PubMedCrossRefGoogle Scholar
  43. 43.
    Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of ­bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2009;27(7):1069–74.PubMedCrossRefGoogle Scholar
  44. 44.
    Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol. 2010;116:181–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Richel I, Zum Vorde Sive Bording PJ, Rietbroek R, Van der Velden J, Van Dijk JDP, Schilthuis MS, Westermann AM. Phase II study of Carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer. Gynecol Oncol. 2004;95:680–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Hung C, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev. 2008;222:43–69.PubMedCrossRefGoogle Scholar
  47. 47.
    Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med. 2002;346:1752–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Cleveland Clinic, Fellow in Gynecologic OncologyWomen’s Health InstituteClevelandUSA
  2. 2.Cleveland Clinic FoundationClevelandUSA
  3. 3.Cleveland Clinic, Section Gynecologic OncologyWomen’s Health InstituteClevelandUSA

Personalised recommendations